Since 1989, Cancer Progress is an oncology conference that invites discussion about scientific progress from a development, regulatory, clinical, commercial and investment perspective.
The 32nd annual meeting will take place on May 4 - 6, 2021 in a virtual format with the theme “Inspiring cancer progress through engaged stakeholder dialogue”. This event will provide learning experience for participants in terms of the quality of information, coverage of issues and value of professional contacts.
Our CEO, Laurent Levy will participate as a panelist on May 4th from 10:15am to 11:30 am in the session "Climbing the Highest Peak : Targeting PD-1/L1 Failures in Solid Tumors". Moderated by Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, and James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting, the session will focus on perhaps the most active area of drug development in Oncology: the effort to improve upon outcomes with checkpoint inhibitors (CPI) by combining agents post failure of the checkpoint with the CPI to resensitize the tumor microenvironment and enable patients to continue to derive benefit from immunotherapies.
Our Business Development team is looking forward to meeting with partners who are interested to find out more about our work. We are available to schedule a meeting at your convenience via email at BD@nanobiotix.com.
The European Society for Medical Oncology (ESMO) Annual Meeting will be virtual this year from 18th to 22nd September. This conference is the opportunity for medical oncologists and other oncology professionals from the many related fields to come together. Pr. Le Tourneau and Pr. De Baere will be there presenting datas.
